[go: up one dir, main page]

PE20020062A1 - 5-AMINO-PIRAZOLO-[4,3-e]-1,2,4-TRIAZOLO[1,5-c]PIRIMIDINA COMO ANTAGONISTAS RECEPTORES DE ADENOSINA A2a - Google Patents

5-AMINO-PIRAZOLO-[4,3-e]-1,2,4-TRIAZOLO[1,5-c]PIRIMIDINA COMO ANTAGONISTAS RECEPTORES DE ADENOSINA A2a

Info

Publication number
PE20020062A1
PE20020062A1 PE2001000475A PE2001000475A PE20020062A1 PE 20020062 A1 PE20020062 A1 PE 20020062A1 PE 2001000475 A PE2001000475 A PE 2001000475A PE 2001000475 A PE2001000475 A PE 2001000475A PE 20020062 A1 PE20020062 A1 PE 20020062A1
Authority
PE
Peru
Prior art keywords
alkyl
phenyl
halogen
triazolo
pyrazolo
Prior art date
Application number
PE2001000475A
Other languages
English (en)
Inventor
Craig D Boyle
Samuel Chackalamannil
William J Greenlee
Yan Xia
Bernard R Neustadt
Lisa S Silverman
Deen Tulshian
Neil Lindo
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of PE20020062A1 publication Critical patent/PE20020062A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

SE REFIERE A COMPUESTOS 5-AMINO-PIRAZOLO-[4,3-e]-1,2,4-TRIAZOLO[1,5-c]PIRIMIDINA DE FORMULA I DONDE R ES R1-FURANILO, R1-TIENILO, R1-PIRIDILO, ENTRE OTROS; X ES ALQUILENO, COCH2; Y ES NR2CH2CH2NR3, OCH2CH2NR2, O, S, CH2S, (CH2)2NH, GRUPO a; m Y n SON 2-3; Q ES N, CH, COH, ENTRE OTROS; Z ES R5-FENILO, R5-FENILALQUILO, R5-HETEROARILO, DIFENILMETILO, GRUPO b, R6CO, ENTRE OTROS; Z E Y SON PIPERIDINILO, FENILO, GRUPO c; R1 ES H, ALQUILO C1-C6, CF3, HALOGENO, NO2; R2, Y R3 SON H, ALQUILO C1-C6; R4 ES H, ALQUILO C1-C6; R5 ES H, HALOGENO, ALQUILO C1-C6, OH, ALCOXI C1-C6, ENTRE OTROS; R6 ES ALQUILO C1-C6, R5-FENILO, TIENILO, ENTRE OTROS; R7 ES ALQUILO C1-C6, R5-FENILO, ENTRE OTROS; R8 ES H, ALQUILO C1-C6 O R7 Y R8 SON (CH2)p-A-(CH2)q; p Y q SON 2-3; A ES UN ENLACE, CH2, S, O; R9 ES H, ALQUILO C1-C6, OH, ALCOXI C1-C6, HALOGENO, ENTRE OTROS; R10 ES H, HALOGENO, ALQUILO C1-C6, ENTRE OTROS; R11 ES H, ALQUILO C1-C6, FENILO, ENTRE OTROS; R12 ES H, ALQUILO C1-C6; R13 ES ALQUILO C1-C6-CO, ALQUILO C1-C6-SO2. TAMBIEN SE REFIERE A UN PROCEDIMIENTO PARA LA PREPARACION. LOS COMPUESTOS I SON ANTAGONISTAS DE RECEPTORES DE ADENOSINA A2a Y PUEDEN SER UTILES PARA EL TRATAMIENTO DE DEPRESION, ENFERMEDADES COGNITIVAS, ENFERMEDADES NEURODEGENERATIVAS, APOPLEJIA, PARKINSON
PE2001000475A 2000-05-26 2001-05-24 5-AMINO-PIRAZOLO-[4,3-e]-1,2,4-TRIAZOLO[1,5-c]PIRIMIDINA COMO ANTAGONISTAS RECEPTORES DE ADENOSINA A2a PE20020062A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US20714300P 2000-05-26 2000-05-26

Publications (1)

Publication Number Publication Date
PE20020062A1 true PE20020062A1 (es) 2002-02-02

Family

ID=22769372

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2001000475A PE20020062A1 (es) 2000-05-26 2001-05-24 5-AMINO-PIRAZOLO-[4,3-e]-1,2,4-TRIAZOLO[1,5-c]PIRIMIDINA COMO ANTAGONISTAS RECEPTORES DE ADENOSINA A2a

Country Status (31)

Country Link
US (4) US6630475B2 (es)
EP (1) EP1283839B1 (es)
JP (3) JP4574112B2 (es)
KR (1) KR100520907B1 (es)
CN (2) CN1247588C (es)
AR (1) AR028621A1 (es)
AT (1) ATE293627T1 (es)
AU (2) AU2001268089C1 (es)
BR (1) BRPI0111015B8 (es)
CA (1) CA2410237C (es)
CZ (1) CZ303790B6 (es)
DE (1) DE60110219T2 (es)
DK (1) DK1283839T3 (es)
EC (1) ECSP024364A (es)
ES (1) ES2237576T3 (es)
HK (1) HK1049007B (es)
HU (1) HU230420B1 (es)
IL (3) IL152726A0 (es)
MX (1) MXPA02011625A (es)
MY (1) MY132006A (es)
NO (1) NO325008B1 (es)
NZ (1) NZ522326A (es)
PE (1) PE20020062A1 (es)
PL (1) PL218764B1 (es)
PT (1) PT1283839E (es)
RU (1) RU2315053C2 (es)
SI (1) SI1283839T1 (es)
SK (1) SK287748B6 (es)
TW (1) TWI288137B (es)
WO (1) WO2001092264A1 (es)
ZA (1) ZA200208898B (es)

Families Citing this family (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2237576T3 (es) * 2000-05-26 2005-08-01 Schering Corporation Antagonistas del receptor a2a de adenosina.
CA2459304A1 (en) * 2001-09-13 2003-03-20 Schering Corporation Combination of an adenosine a2a receptor antagonist and an antidepressant or anxiolytic
JP4545437B2 (ja) 2001-10-15 2010-09-15 シェーリング コーポレイション アデノシンａ２ａ受容体アンタゴニストとしてのイミダゾ（４，３−ｅ）−１，２，４−トリアゾロ（１，５−ｃ）ピリミジン
FR2832405B1 (fr) * 2001-11-19 2004-12-10 Sanofi Synthelabo Tetrahydropyridyl-alkyl-heterocycles azotes, procede pour leur preparation et compositions pharmaceutiques les contenant
KR20050044600A (ko) 2001-11-30 2005-05-12 쉐링 코포레이션 [1,2,4]-트리아졸 바이사이클릭 아데노신 Ａ2ａ 수용체길항제
PE20030739A1 (es) 2001-11-30 2003-08-28 Schering Corp Antagonistas del receptor de adenosina a2a
HUP0402018A3 (en) 2001-11-30 2008-06-30 Schering Corp 5-amino-7h-pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidine derivatives, their use and pharmaceutical compositions containing them
EP2260850B1 (en) 2002-01-28 2018-07-04 Kyowa Hakko Kogyo Co., Ltd A2A receptor antagonists for use in the treatment of movement disorders
IL160133A0 (en) * 2002-05-30 2004-06-20 King Pharmaceuticals Res & Dev Pharmaceutically active compounds having a tricyclic pyrazolotriazolopyrimidine ring structure and methods of use
US20060106040A1 (en) * 2002-12-19 2006-05-18 Michael Grzelak Adenosine A2a receptor antagonists for the treatment of extra-pyramidal syndrome and other movement disorders
DE60335294D1 (de) 2002-12-19 2011-01-20 Schering Corp Dlung des extrapyramidalen syndroms
WO2004092172A2 (en) 2003-04-09 2004-10-28 Biogen Idec Ma Inc. Triazolo[1,5-c]pyrimidines and pyrazolo[1,5-c]pyrimidines useful as a2a adenosin e receptor antagonists
TWI375677B (en) * 2003-04-23 2012-11-01 Schering Corp 2-alkynyl-and 2-alkenyl-pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine a2a receptor antagonists
EP1631294B1 (en) * 2003-06-10 2010-09-15 Kyowa Hakko Kirin Co., Ltd. A method of treating an anxiety disorder
JP2006527212A (ja) * 2003-06-12 2006-11-30 ノボ　ノルディスク　アクティーゼルスカブ ホルモン感受性リパーゼの阻害剤として使用するための、置換ピペラジンカルバメート
AU2004283751B2 (en) * 2003-10-24 2011-05-19 Exelixis, Inc. p70S6 kinase modulators and method of use
SI1678182T1 (sl) 2003-10-28 2007-06-30 Schering Corp Postopek priprave substituiranih 5-amino-pirazolo- (4,3-e)-1,2,4-triazolo(1,5-)pirimidinov
JP2007513091A (ja) * 2003-12-01 2007-05-24 シェーリング　コーポレイション 置換された５−アミノ−ピラゾロ−［４，３−ｅ］−１，２，４−トリアゾロ［１，５−ｃ］ピリミジンを調製するための方法
AU2004303425C1 (en) * 2003-12-19 2010-02-18 Schering Corporation Pharmaceutical compositions
PE20060185A1 (es) * 2004-04-21 2006-03-20 Schering Corp ANTAGONISTA DEL RECEPTOR A2A DE LA ADENOSINA CON ESTRUCTURA DE PIRAZOLO--[4,3-e]-1,2,4-TRIAZOLO-[1,5-c]-PIRIMIDINA
JPWO2006132275A1 (ja) * 2005-06-07 2009-01-08 協和醗酵工業株式会社 運動障害の予防および／または治療剤
EP1934227B1 (en) * 2005-09-19 2011-12-21 Schering Corporation 2-HETEROARYL-PYRAZOLO-[4, 3-e]-1, 2, 4-TRIAZOLO-[1,5-c]-PYRIMIDINE AS ADENOSINE A2a RECEPTOR ANTAGONISTS
AR056080A1 (es) * 2005-09-23 2007-09-19 Schering Corp 7-[2-[4-(6-fluoro-3-metil-1,2-benciosoxazol-5-il)-1-piperazinil]etil]-2-(1-propinil)-7h-pirazol-[4,3-e]-[1,2,4]-triazol-[1,5-c] -pirimidin-5-amine
ES2273599B1 (es) 2005-10-14 2008-06-01 Universidad De Barcelona Compuestos para el tratamiento de la fibrilacion auricular.
WO2008008398A2 (en) * 2006-07-14 2008-01-17 Shionogi & Co., Ltd. Oxime compounds and the use thereof
TW200840566A (en) * 2006-12-22 2008-10-16 Esteve Labor Dr Heterocyclyl-substituted-ethylamino-phenyl derivatives, their preparation and use as medicaments
US7691869B2 (en) 2007-03-30 2010-04-06 King Pharmaceuticals Research And Development, Inc. Pyrrolotriazolopyrimidine derivatives, pharmaceutical compositions containing them and methods of treating conditions and diseases mediated by the adenosine A2A receptor activity
WO2009110955A2 (en) * 2008-02-29 2009-09-11 Albert Einstein College Of Medicine Of Yeshiva University Ketoconazole-derivative antagonists of human pregnane x receptor and uses thereof
CA2717172A1 (en) 2008-03-04 2009-09-11 Schering Corporation 1,2,4-triazolo[4,3-c]pyrimidin-3-one and pyrazolo [4,3-e] -1,2,4-triazolo [4,3-c] pyrimidin-3-one compounds for use as adenosine a2a receptor antagonists
EP2274007B1 (en) 2008-03-10 2016-12-14 Cornell University Modulation of blood brain barrier permeability
TWI473614B (zh) * 2008-05-29 2015-02-21 Kyowa Hakko Kirin Co Ltd Anti-analgesic inhibitors
NZ590793A (en) * 2008-07-23 2012-07-27 Kyowa Hakko Kirin Co Ltd Therapeutic agent for migraine
US20100093702A1 (en) * 2008-10-13 2010-04-15 Barbay J Kent METHYLENE AMINES OF THIENO[2,3-d]PYRIMIDINE AND THEIR USE AS ADENOSINE A2a RECEPTOR ANTAGONISTS
EP2379556A1 (en) 2008-12-30 2011-10-26 ArQule, Inc. Substituted 1h-pyrazolo[3,4-d]pyrimidine-6-amine compounds
US20120053182A1 (en) 2009-01-20 2012-03-01 Schering Corporation Methods of alleviating or treating signs and/or symptoms associated with moderate to severe parkinson's disease
WO2010084160A1 (en) 2009-01-21 2010-07-29 Oryzon Genomics S.A. Phenylcyclopropylamine derivatives and their medical use
AU2010222289B2 (en) 2009-03-13 2013-07-11 Advinus Therapeutics Private Limited Substituted fused pyrimidine compounds
EP2414361A1 (en) 2009-03-31 2012-02-08 ArQule, Inc. Substituted heterocyclic compounds
US8537177B2 (en) * 2009-06-15 2013-09-17 Marvell World Trade Ltd. System and methods for gamut bounded saturation adaptive color enhancement
EP2462144B1 (en) 2009-08-07 2017-09-20 Merck Sharp & Dohme Corp. PROCESS FOR PREPARING A 2-ALKYNYL SUBSTITUTED 5-AMINO-PYRAZOLO-[4,3-e]-1,2,4-TRIAZOLO[1,5-c]PYRIMIDINE
EP2480528B1 (en) 2009-09-25 2018-08-29 Oryzon Genomics, S.A. Lysine specific demethylase-1 inhibitors and their use
WO2011042217A1 (en) 2009-10-09 2011-04-14 Oryzon Genomics S.A. Substituted heteroaryl- and aryl- cyclopropylamine acetamides and their use
WO2011101861A1 (en) 2010-01-29 2011-08-25 Msn Laboratories Limited Process for preparation of dpp-iv inhibitors
WO2011106574A2 (en) 2010-02-24 2011-09-01 Oryzon Genomics, S.A. Inhibitors for antiviral use
WO2011106573A2 (en) 2010-02-24 2011-09-01 Oryzon Genomics, S.A. Lysine demethylase inhibitors for diseases and disorders associated with hepadnaviridae
WO2011131697A1 (en) 2010-04-19 2011-10-27 Oryzon Genomics S.A. Lysine specific demethylase-1 inhibitors and their use
CN104892525A (zh) 2010-07-29 2015-09-09 奥瑞泽恩基因组学股份有限公司 Lsd1的基于芳基环丙胺的脱甲基酶抑制剂及其医疗用途
US9006449B2 (en) 2010-07-29 2015-04-14 Oryzon Genomics, S.A. Cyclopropylamine derivatives useful as LSD1 inhibitors
CN103261202B (zh) * 2010-09-24 2016-01-20 阿迪维纳斯疗法有限公司 作为腺苷受体拮抗剂的稠合三环化合物
WO2012045883A1 (en) 2010-10-08 2012-04-12 Oryzon Genomics S.A. Cyclopropylamine inhibitors of oxidases
WO2012072713A2 (en) 2010-11-30 2012-06-07 Oryzon Genomics, S.A. Lysine demethylase inhibitors for diseases and disorders associated with flaviviridae
WO2012107498A1 (en) 2011-02-08 2012-08-16 Oryzon Genomics S.A. Lysine demethylase inhibitors for myeloproliferative disorders
WO2012127472A1 (en) * 2011-03-22 2012-09-27 Mapi Pharma Ltd. Process and intermediates for the preparation of preladenant and related compounds
WO2012129381A1 (en) * 2011-03-22 2012-09-27 Concert Pharmaceuticals Inc. Deuterated preladenant
WO2013024474A1 (en) * 2011-08-18 2013-02-21 Mapi Phrarma Ltd. Polymorphs of preladenant
IN2014CN03337A (es) 2011-10-20 2015-07-03 Oryzon Genomics Sa
EP2768805B1 (en) 2011-10-20 2020-03-25 Oryzon Genomics, S.A. (hetero)aryl cyclopropylamine compounds as lsd1 inhibitors
WO2014071512A1 (en) * 2012-11-06 2014-05-15 Universite Laval Combination therapy and methods for the treatment of respiratory diseases
WO2014101120A1 (en) * 2012-12-28 2014-07-03 Merck Sharp & Dohme Corp. Heterobicyclo-substituted-7-methoxy-[1,2,4]triazolo[1,5-c]quinazolin-5-amine compounds with a2a antagonist properties
CA2967944C (en) 2014-11-18 2020-11-17 Merck Sharp & Dohme Corp. Aminopyrazine compounds with a2a antagonist properties
EP3253390B1 (en) 2015-02-06 2022-04-13 Merck Sharp & Dohme Corp. Aminoquinazoline compounds as a2a antagonist
EP3307067B1 (en) 2015-06-11 2022-11-02 Merck Sharp & Dohme LLC Aminopyrazine compounds with a2a antagonist properties
WO2017008205A1 (en) 2015-07-10 2017-01-19 Merck Sharp & Dohme Corp. Substituted aminoquinazoline compounds as a2a antagonist
US9687475B1 (en) 2016-03-24 2017-06-27 Ezra Pharma Llc Extended release pharmaceutical formulations with controlled impurity levels
US9675585B1 (en) 2016-03-24 2017-06-13 Ezra Pharma Extended release pharmaceutical formulations
KR102640927B1 (ko) * 2017-03-30 2024-02-27 아이테오스 벨지움 에스에이 A2a 억제제로서의 2-옥소-티아졸 유도체 및 암 치료에 사용하기 위한 화합물
TWI801372B (zh) * 2017-03-30 2023-05-11 比利時商艾特歐斯比利時有限公司 作為a2a抑制劑的硫胺甲酸酯衍生物以及用於癌症治療的方法
EP3723754A4 (en) 2017-12-13 2021-05-19 Merck Sharp & Dohme Corp. IMIDAZO [1,2-C] QUINAZOLINE-5-AMINE COMPOUNDS WITH PROPERTIES OF A2A ANTAGONIST
US11407758B2 (en) 2018-01-04 2022-08-09 Impetis Biosciences Ltd. Tricyclic compounds, compositions and medicinal applications thereof
CR20200441A (es) 2018-02-27 2021-03-15 Incyte Corp Imidazopirimidinas y triazolopirimidinas como inhibidores de a2a / a2b
CN108276345A (zh) * 2018-03-22 2018-07-13 重庆奥舍生物化工有限公司 一种药物中间体嘧啶-5-甲醛的制备方法
US11472811B2 (en) * 2018-04-08 2022-10-18 Beigene, Ltd. Pyrazolotriazolopyrimidine derivatives as A2A receptor antagonist
MX2020012376A (es) 2018-05-18 2021-03-09 Incyte Corp Derivados de pirimidina fusionados como inhibidores de los receptores de adenosina a2a/a2b.
CN108864114B (zh) 2018-06-04 2020-11-06 应世生物科技(南京)有限公司 选择性a2a受体拮抗剂
IL279829B2 (en) 2018-07-05 2025-05-01 Incyte Holdings Corp Fused pyrazine derivatives as A2A/A2B inhibitors
CN110742893B (zh) * 2018-07-23 2024-04-05 百济神州(北京)生物科技有限公司 A2a受体拮抗剂治疗癌症的方法
PE20211768A1 (es) 2018-11-30 2021-09-07 Merck Sharp & Dohme Derivados de amino triazolo quinazolina 9-sustituidos como antagonistas del receptor de adenosina, composiciones farmaceuticas y su uso
BR112021011948A2 (pt) 2018-12-20 2021-09-08 Incyte Corporation Compostos de imidazopiridazina e imidazopiridina e usos dos mesmos
TWI829857B (zh) 2019-01-29 2024-01-21 美商英塞特公司 作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶
WO2020227156A1 (en) * 2019-05-03 2020-11-12 Nektar Therapeutics Adenosine 2 receptor antagonists
DE102019116986A1 (de) 2019-06-24 2020-12-24 Helmholtz-Zentrum Dresden-Rossendorf E. V. Deuterierte 7-(3-(4-(2-([18F]Fluor)ethoxy)phenyl)propyl)-2-(furan-2-yl)-7H-pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidin-5-amin-Derivate
US20230024108A1 (en) * 2019-07-17 2023-01-26 Teon Therapeutics, Inc. Adenosine a2a receptor antagonists
CN112479956A (zh) 2019-07-30 2021-03-12 杭州阿诺生物医药科技有限公司 一种用于制备腺苷受体抑制剂中间体的方法
CN112592354B (zh) 2019-07-30 2022-05-27 厦门宝太生物科技股份有限公司 一种异噁唑并嘧啶类杂环化合物的制备方法
CN111072675A (zh) * 2019-12-12 2020-04-28 广东东阳光药业有限公司 含氮稠合三环衍生物及其用途
CN113773327B (zh) * 2021-09-13 2022-07-15 八叶草健康产业研究院(厦门)有限公司 一种吡唑并嘧啶并三唑环类化合物的制备方法
CN118812539B (zh) * 2024-06-19 2025-11-28 苏州大学 一种5-氨基三唑并嘧啶衍生物及其制备方法
CN118812544A (zh) * 2024-06-19 2024-10-22 厦门大学 一种腺苷a2ar靶向小分子化合物、核素标记探针及其制备方法、应用和药物组合物

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0217748B1 (en) 1985-09-30 1991-02-06 Ciba-Geigy Ag 2-Substituted-e-fused-[1,2,4,]triazolo-[1,5-c]pyrimidines pharmaceutical compositions and uses thereof
SU1739850A3 (ru) * 1987-08-31 1992-06-07 Такеда Кемикал Индастриз, Лтд (Фирма) Способ получени конденсированных производных пиразоло[3,4- @ ]пиримидина
IT1264901B1 (it) * 1993-06-29 1996-10-17 Schering Plough S P A Analoghi eterociclici di 1,2,4-triazolo(15-c)pirimidine ad attivita' antagonista per il recettore a2 dell'adenosina
ES2165393T3 (es) 1993-07-27 2002-03-16 Kyowa Hakko Kogyo Kk Remedio contra la enfermedad de parkinson.
IT1277392B1 (it) 1995-07-28 1997-11-10 Schering Plough S P A Analoghi eterociclici di 1,2,4-triazolo(1,5-c]pirimidine ad attivita' antagonista per il recettore a2a dell'adenosina
IT1291372B1 (it) * 1997-05-21 1999-01-07 Schering Plough S P A Uso di analoghi eterociclici di 1,2,4-triazolo (1,5-c) pirimidine per la preparazione di medicamenti utili per il trattamento delle malattie
ES2237576T3 (es) * 2000-05-26 2005-08-01 Schering Corporation Antagonistas del receptor a2a de adenosina.
HUP0402018A3 (en) * 2001-11-30 2008-06-30 Schering Corp 5-amino-7h-pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidine derivatives, their use and pharmaceutical compositions containing them
DE60335294D1 (de) * 2002-12-19 2011-01-20 Schering Corp Dlung des extrapyramidalen syndroms
SI1678182T1 (sl) * 2003-10-28 2007-06-30 Schering Corp Postopek priprave substituiranih 5-amino-pirazolo- (4,3-e)-1,2,4-triazolo(1,5-)pirimidinov
JP2007513091A (ja) * 2003-12-01 2007-05-24 シェーリング　コーポレイション 置換された５−アミノ−ピラゾロ−［４，３−ｅ］−１，２，４−トリアゾロ［１，５−ｃ］ピリミジンを調製するための方法
PE20060185A1 (es) * 2004-04-21 2006-03-20 Schering Corp ANTAGONISTA DEL RECEPTOR A2A DE LA ADENOSINA CON ESTRUCTURA DE PIRAZOLO--[4,3-e]-1,2,4-TRIAZOLO-[1,5-c]-PIRIMIDINA
EP1934227B1 (en) * 2005-09-19 2011-12-21 Schering Corporation 2-HETEROARYL-PYRAZOLO-[4, 3-e]-1, 2, 4-TRIAZOLO-[1,5-c]-PYRIMIDINE AS ADENOSINE A2a RECEPTOR ANTAGONISTS

Also Published As

Publication number Publication date
WO2001092264A1 (en) 2001-12-06
JP4938348B2 (ja) 2012-05-23
CA2410237C (en) 2008-01-08
MXPA02011625A (es) 2003-03-27
NO325008B1 (no) 2008-01-14
MY132006A (en) 2007-09-28
SI1283839T1 (es) 2005-08-31
US6897216B2 (en) 2005-05-24
CN1451007A (zh) 2003-10-22
IL220174A (en) 2015-07-30
KR100520907B1 (ko) 2005-10-11
HU230420B1 (hu) 2016-05-30
TWI288137B (en) 2007-10-11
CA2410237A1 (en) 2001-12-06
HK1049007B (en) 2005-09-16
NO20025651L (no) 2003-01-23
IL152726A0 (en) 2003-06-24
US20050026932A1 (en) 2005-02-03
BRPI0111015B1 (pt) 2017-11-07
ATE293627T1 (de) 2005-05-15
NZ522326A (en) 2006-03-31
JP2003535094A (ja) 2003-11-25
ZA200208898B (en) 2004-03-01
CN100384847C (zh) 2008-04-30
EP1283839B1 (en) 2005-04-20
HUP0600239A2 (en) 2006-07-28
US6630475B2 (en) 2003-10-07
AU2001268089B2 (en) 2005-04-28
IL220174A0 (en) 2012-07-31
PL218764B1 (pl) 2015-01-30
AU2001268089C1 (en) 2006-04-13
BR0111015A (pt) 2005-01-11
HK1049007A1 (en) 2003-04-25
ECSP024364A (es) 2003-03-31
CN1800186A (zh) 2006-07-12
JP4574112B2 (ja) 2010-11-04
JP2006219497A (ja) 2006-08-24
SK287748B6 (sk) 2011-08-04
NO20025651D0 (no) 2002-11-25
CZ303790B6 (cs) 2013-05-09
PT1283839E (pt) 2005-08-31
HUP0600239A3 (en) 2008-06-30
DK1283839T3 (da) 2005-07-25
US20020099061A1 (en) 2002-07-25
IL152726A (en) 2012-07-31
ES2237576T3 (es) 2005-08-01
SK16712002A3 (sk) 2003-08-05
RU2315053C2 (ru) 2008-01-20
BRPI0111015B8 (pt) 2021-05-25
US20040023997A1 (en) 2004-02-05
EP1283839A1 (en) 2003-02-19
DE60110219T2 (de) 2006-03-09
DE60110219D1 (de) 2005-05-25
AU6808901A (en) 2001-12-11
CN1247588C (zh) 2006-03-29
PL360472A1 (en) 2004-09-06
CZ20023886A3 (cs) 2003-02-12
USRE44205E1 (en) 2013-05-07
KR20030003746A (ko) 2003-01-10
JP2007145875A (ja) 2007-06-14
US7067655B2 (en) 2006-06-27
AR028621A1 (es) 2003-05-14

Similar Documents

Publication Publication Date Title
PE20020062A1 (es) 5-AMINO-PIRAZOLO-[4,3-e]-1,2,4-TRIAZOLO[1,5-c]PIRIMIDINA COMO ANTAGONISTAS RECEPTORES DE ADENOSINA A2a
PE20030477A1 (es) ANTAGONISTAS DEL RECEPTOR DE ADENOSINA A2a
PE20060185A1 (es) ANTAGONISTA DEL RECEPTOR A2A DE LA ADENOSINA CON ESTRUCTURA DE PIRAZOLO--[4,3-e]-1,2,4-TRIAZOLO-[1,5-c]-PIRIMIDINA
PE20051039A1 (es) [1,8] naftiridin-2-onas y compuestos relacionados
CO5700778A2 (es) Administracion combinada de una indolinona con un agente quimioterapeutico para trastornos de proliferacion celular
PE20020366A1 (es) Derivados de piperazina como ligandos del receptor 5ht2
PE20030739A1 (es) Antagonistas del receptor de adenosina a2a
AR004516A1 (es) Derivados de pirimidina, su uso, procedimientos para prepararlos y medicamentos que los contienen
PE20081192A1 (es) Tratamiento del dolor
PE20010629A1 (es) Derivados de triazolpiridinamina como ligandos de receptores de adenosina
PE20130012A1 (es) Derivados de pirazol como inhibidores de jak
PE20030129A1 (es) Imidazotriazinas
PE46899A1 (es) Derivados de n-fenil-sulfonamida
PE20040197A1 (es) Pirazolopiridinas sustituidas con carbamato
PE20010964A1 (es) Derivados de tiazolilamida
PE20091068A1 (es) Compuestos pirrolo[3,2-d]pirimidina y su uso como inhibidores de quinasa pi3 y quinasa mtor
AR072756A2 (es) Intermediarios para la preparacion; derivados de triazolo[4,5-d]pirimidina, utiles como antitromboticos
PE20020406A1 (es) 7-OXO-PIRIDO[2,3-d]PIRIMIDINAS 2,6-DISUSTITUIDAS COMO INHIBIDORES DE LAS PROTEINAS CINASAS
PE20030727A1 (es) 17OALQUIL-17ß-OXI-ESTRATRIENOS, PRODUCTOS INTERMEDIARIOS PARA SU PREPARACION Y COMPOSICIONES FARMACEUTICAS QUE LOS CONTIENEN
AR035068A1 (es) Compuestos de pirimidinona, composiciones farmaceuticas que los comprenden, uso de tales compuestos en la fabricacion de medicamentos y proceso para la preparacion de dichos compuestos
AR065863A1 (es) Derivados de imidazolidinona
PE109598A1 (es) Pirrolcarboxamidas condensadas, utiles como ligandos de receptores cerebrales gaba
PE20030761A1 (es) Derivados del 7-amino-benzotiazol
PE20030653A1 (es) COMPUESTOS BICICLICOS[1,2,4]-TRIAZOL COMO ANTAGONISTAS DE RECEPTORES DE ADENOSINA A2a
PE20020844A1 (es) Derivados de imidazolilo como inhibidores del factor de liberacion de la corticotropina

Legal Events

Date Code Title Description
FG Grant, registration